Image For Activity Cover
April 27, 2021- ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
First time Users
First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, login before proceeding.
Course Information

ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Tuesday, April 27, 2021

11:00am – 12:00 pm ET


Course Description

Drs. Phillip Michaels, Matthew Weinstock, and Ioannis Vlachos present a case of a middle-aged female with a longstanding history of a slow growing mediastinal mass that has failed steroids and radiation therapy and ultimately elected for resection. By molecular genetic analysis, no definitive pathogenic variant was identified. However, by chromosomal microarray, multiple copy number changes were present with a pattern suggestive of follicular dendritic cell sarcoma, but histologic examination does not confirm such a diagnosis. Pathology evaluation and molecular profiling will be presented, along with the patient case history for this enigmatic case.

Each presentation in the case series will feature an oncologist and clinical laboratory scientist as speakers. The oncologist will present the clinical case vignette and the clinical laboratory scientist will present the genomic data and interpretation.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.


Presentations followed by live Q&A. 

Learning Objectives

At the conclusion of this session, participants should be able to:

  1. Identify the clinical guidelines, assays, and tools used during the diagnostic odyssey of this patient.
  2. Explain the significance of negative findings in cancer NGS cases.
  3. Discuss opportunities that may lead to a definitive diagnosis.



Gordana Raca, MD, PhD, FACMG (moderator)

Children’s Hospital of Los Angeles

Director, Clinical Cytogenomics Laboratory, Center for Personalized Medicine (CPM)

Associate Professor of Clinical Pathology, Keck School of Medicine of USC


Phillip Michaels, MD

Hematopathologist, Molecular genetic pathologist, Assistant Medical Director

Beth Israel Deaconess Medical Center, Harvard Medical School

Dr. Phillip Michaels received his medical degree from the University of Tennessee College of Medicine, Memphis, TN. He went on to complete his anatomic and clinical pathology residency as well as hematopathology fellowship at Beth Israel Deaconess Medical Center, Boston, MA. Subsequently, he completed a molecular genetic pathology fellowship in the Harvard Medical School Genetics Training Program, Boston, MA. His main academic interests include the clinical and diagnostic utility of next-generation sequencing (NGS) in myeloid and lymphoid neoplasms, microarray analyses of B-cell lymphomas, genotypic and phenotypic correlation of aggressive lymphomas, NGS assessment of myeloid neoplasms with germline predisposition, as well as resident and fellow education in molecular genetic pathology and hematopathology.



 Matthew J. Weinstock, MD

Hematologist, Instructor of Medicine

Beth Israel Deaconess Medical Center, Harvard Medical School


Dr. Matthew Weinstock received his medical degree from Columbia University.  He went on to complete residency in Internal Medicine at Brigham and Women's Hospital, and Fellowship in Hematology and Oncology at Beth Israel Deaconess Medical Center, both in Boston, MA. He is currently an Attending Physician in the Hematologic Malignancy and Bone Marrow Transplant group at Beth Israel Deaconess Medical Center and an Instructor in Medicine at Harvard Medical School. His clinical and research interests include immunotherapeutic approaches for B- and T-cell Non-Hodgkin Lymphomas and Hodgkin Lymphoma.



Ioannis Vlachos, PhD

Assistant Professor, Co-Director of Bioinformatics Program

Harvard Medical School


Dr. Vlachos is an Assistant Professor of Pathology in Harvard Medical School and the Director of the Bioinformatics Unit of the Non-coding RNA Precision Diagnostics and Bioinformatics Core, Harvard Initiative for RNA Medicine, Beth Israel Deaconess Medical Center. He is also the Co-Director of the Bioinformatics Program at the Cancer Research Institute (CRI) and an Associate Member of the Broad Institute of MIT and Harvard.


Financial Disclosures

Disclosure Statement

 It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Disclosure must include financial relationships of the individual and those of their spouse/partner. Individuals who do not disclose will be disqualified from participating in a CME activity.

This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity. ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.


ACMG will follow the ACCME’s expectation that no employees or owners of commercial interests will be involved as planners/faculty/presenters of a CME accredited activity.

The ACCME definition of a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

Diagnostic laboratories are not considered commercial interests unless they are owned by or have a sister organization which is a commercial interest.

Planning Committee and ACMG Staff*

The following have nothing to disclose.

Shruti Rao, MS, MBA

Beth Pitel, MS, CG(ASCP)

Gordana Raca, MD, PhD, FACMG

Alex Wagner, PhD

*Maximilian Muenke, MD, FACMG

*Jane Radford, MHA, CHCP

Presenters Disclosures

Phillip Michaels, MD

Nothing to disclose


Ioannis Vlachos, PhD

Dr. Vlachos has disclosed that he is receives grant research support from Botanisol Analytics, and he is a consultant for Mosaic Research.


Matthew J. Weinstock, MD

Nothing to disclose


Educational Credit


Accreditation Statement

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation Statement

The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. Deadline to claim educational credits is within 30 days from the date of the webinar. ACMG will not accept any credit request for live meetings after that period.


HIPAA Compliance

The ACMG supports medical information privacy.  While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized.  All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information.  If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the ACMG HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available on request.


Content Validation

ACMG follows the ACCME policy on Content Validation for CME activities, which requires:


Content Validation and Fair Balance

  1. ACMG follows the ACCME policy on Content Validation for CME activities, which requires:
  1. All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection and analysis.


  1. Activities that fall outside the definition of CME/CE; “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA) will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
  2. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality.  If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.


Off-label Uses of Products

When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.



The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Availability: No future session
Expires on 05/27/2021
Cost: FREE
Credit Offered: 1 CME (AMA) Credit
1 CME (Other) Credit
Powered By